Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ICAD 
icad inc (ICAD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ICAD (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
AI Based Fundamental Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Analysis of Past Performance
Type Stock | Historic Profit -68.59% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 56.40M USD | Price to earnings Ratio - | 1Y Target Price 4.75 |
Price to earnings Ratio - | 1Y Target Price 4.75 | ||
Volume (30-day avg) 305378 | Beta 1.96 | 52 Weeks Range 1.18 - 3.78 | Updated Date 04/1/2025 |
52 Weeks Range 1.18 - 3.78 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.21 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-03-10 | When Before Market | Estimate -0.0525 | Actual -0.03 |
Profitability
Profit Margin -28.64% | Operating Margin (TTM) -15.98% |
Management Effectiveness
Return on Assets (TTM) -9.92% | Return on Equity (TTM) -18.09% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 39553985 | Price to Sales(TTM) 2.88 |
Enterprise Value 39553985 | Price to Sales(TTM) 2.88 | ||
Enterprise Value to Revenue 2.02 | Enterprise Value to EBITDA -3.36 | Shares Outstanding 26354200 | Shares Floating 24819067 |
Shares Outstanding 26354200 | Shares Floating 24819067 | ||
Percent Insiders 5.83 | Percent Institutions 23.24 |
Analyst Ratings
Rating 4.75 | Target Price 4.38 | Buy 1 | Strong Buy 3 |
Buy 1 | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
icad inc
Company Overview
History and Background
iCAD, Inc. provides advanced image analysis, workflow solutions and radiation therapy for the early detection and treatment of cancer. Founded in 1984, it has evolved from a computer-aided detection company to a comprehensive cancer detection and therapy solutions provider.
Core Business Areas
- Cancer Detection: Develops and markets advanced image analysis solutions for early breast and lung cancer detection, including AI-powered software for mammography and chest radiography.
- Radiation Therapy: Provides advanced brachytherapy solutions for radiation therapy to treat various cancers and diseases.
Leadership and Structure
The leadership team consists of experienced professionals in medical technology, sales, marketing, and finance. The organizational structure is typical of a publicly traded company, with departments focused on research and development, sales, marketing, and operations.
Top Products and Market Share
Key Offerings
- ProFound AI for Mammography: AI-powered software that analyzes mammograms to detect breast cancer early. iCAD's ProFound AI solutions improve cancer detection rates. Market share data is not publicly available, but iCAD is a significant player in the AI-powered mammography market. Competitors include Hologic, GE Healthcare, and Lunit.
- Xoft Axxent eBx System: An electronic brachytherapy system used for treating early-stage breast cancer. Market share data is unavailable. Competitors include Elekta and Varian Medical Systems.
Market Dynamics
Industry Overview
The cancer detection and radiation therapy market is growing due to an aging population, increasing cancer incidence, and technological advancements. AI and machine learning are increasingly being adopted to improve cancer detection and treatment outcomes.
Positioning
iCAD is positioned as an innovative provider of AI-powered cancer detection and radiation therapy solutions. Its competitive advantages include its proprietary AI algorithms, established customer base, and strong relationships with healthcare providers.
Total Addressable Market (TAM)
The total addressable market for cancer diagnostics and treatment is estimated to be in the tens of billions of dollars. iCAD is positioned to capture a portion of this market through its innovative technologies and strategic partnerships. TAM estimated at $170 billion by 2030.
Upturn SWOT Analysis
Strengths
- Innovative AI-powered technology
- Strong customer relationships
- Established presence in the cancer detection and radiation therapy market
- Proprietary technology
Weaknesses
- Limited financial resources compared to larger competitors
- Dependence on regulatory approvals
- Reliance on a limited number of key products
Opportunities
- Expanding into new geographic markets
- Developing new AI-powered solutions for other types of cancer
- Partnering with larger medical device companies
- Increasing adoption of AI in healthcare
Threats
- Competition from larger medical device companies
- Changes in regulatory requirements
- Technological advancements that could render iCAD's products obsolete
- Economic downturn
Competitors and Market Share
Key Competitors
- Hologic (HOLX)
- GE Healthcare (GE)
- Elekta (EKTAY)
- Varian Medical Systems (SIEMENS_HEALTHINEERS)
Competitive Landscape
iCAD faces intense competition from larger medical device companies with greater financial resources. iCAD's competitive advantages include its innovative AI-powered technology and its focus on early cancer detection.
Major Acquisitions
Growth Trajectory and Initiatives
Historical Growth: iCAD's historical growth has been driven by the adoption of its AI-powered cancer detection solutions and radiation therapy systems. Growth rate needs to be populated dynamically using historical data.
Future Projections: Analyst estimates for iCAD's future growth vary depending on the adoption rate of its AI-powered solutions and the success of its new product launches. Need to update dynamically.
Recent Initiatives: Recent strategic initiatives include expanding its sales and marketing efforts, developing new AI-powered solutions, and partnering with other healthcare providers.
Summary
iCAD is a relatively small company operating in a high-growth market with innovative AI solutions for cancer detection. They face competition from larger, well-established players. The company needs to capitalize on partnerships and expand its market reach. Regulatory approvals and ongoing innovation are crucial for iCAD's success and they need to maintain a strong balance sheet to compete effectively.
Similar Companies
- HOLX
- GE
- EKTAY
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Industry Reports, Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About icad inc
Exchange NASDAQ | Headquaters Nashua, NH, United States | ||
IPO Launch date 1986-12-03 | President, CEO & Executive Chair Ms. Dana R. Brown | ||
Sector Healthcare | Industry Medical Devices | Full time employees - | Website https://www.icadmed.com |
Full time employees - | Website https://www.icadmed.com | ||
iCAD, Inc. engages in the provision of cancer detection and therapy solutions in the United States. It operates through two segments, Detection and Therapy. The company provides ProFound AI for digital breast tomosynthesis and 2D mammography; PowerLook, a density assessment solution; and ProFound Risk, a breast cancer risk analysis. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.